Autoimmune Disease Therapeutics Market to Gain from Increased Acceptance of Biologics by Physicians - European Autoimmune Diseases Therapeutics Markets.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c49960) announces the addition of Frost & Sullivan's new report European Autoimmune Diseases Autoimmune diseases A group of diseases, like rheumatoid arthritis and systemic lupus erythematosus, in which immune cells turn on the body, attacking various tissues and organs. Mentioned in: Complement Deficiencies, Premature Menopause Therapeutics therapeutics Treatment and care to combat disease or alleviate pain or injury. Its tools include drugs, surgery, radiation therapy, mechanical devices, diet, and psychiatry. Markets to their offering. This Frost & Sullivan research service titled European Autoimmune Disease autoimmune disease, any of a number of abnormal conditions caused when the body produces antibodies to its own substances. In rheumatoid arthritis, a group of antibody molecules called collectively RF, or rheumatoid factor, is complexed to the individual's own gamma Therapeutics Market provides an overview of current treatment options, drugs in pipeline and technological advancements in the market. It also a complete analysis of key market drivers, restraints and revenues involved in the current rheumatoid arthritis rheumatoid arthritis Chronic, progressive autoimmune disease causing connective-tissue inflammation, mostly in synovial joints. It can occur at any age, is more common in women, and has an unpredictable course. and multiple sclerosis multiple sclerosis (MS), chronic, slowly progressive autoimmune disease in which the body's immune system attacks the protective myelin sheaths that surround the nerve cells of the brain and spinal cord (a process called demyelination), resulting in damaged areas medications. In this research, Frost & Sullivan's expert analysts thoroughly examine the following therapeutics markets for rheumatoid arthritis and multiple sclerosis. Market Sectors Expert Frost & Sullivan analysts thoroughly examine the following market sectors in this research: -Rheumatoid arthritis therapeutics -Multiple sclerosis sclerosis /scle·ro·sis/ (-ro´sis) an induration or hardening, especially from inflammation and in diseases of the interstitial substance; applied chiefly to such hardening of the nervous system or to hardening of the blood vessels. therapeutics Market Overview Autoimmune Disease Therapeutics Market to Gain from Increased Acceptance of Biologics by Physicians The European autoimmune diseases therapeutics market is set to witness sustained growth in the coming years. Autoimmune diseases are caused by body's immune responses immune response n. An integrated bodily response to an antigen, especially one mediated by lymphocytes and involving recognition of antigens by specific antibodies or previously sensitized lymphocytes. directed on its own tissues. The immune system immune system Cells, cell products, organs, and structures of the body involved in the detection and destruction of foreign invaders, such as bacteria, viruses, and cancer cells. Immunity is based on the system's ability to launch a defense against such invaders. is designed to attack the infections caused by foreign bacteria and viruses. However, in an autoimmune disease, the immune cells in the body recognise the body's own tissues as 'foreign' and the antibodies released by the immune cells act on various tissues in the body, leading to various disease conditions. There are over 70 autoimmune diseases including rheumatoid arthritis (RA), multiple sclerosis (MS) and psoriasis psoriasis (sôrī`əsĭs), occasionally acute but usually chronic and recurrent inflammation of the skin. The exact cause is unknown, but the disease appears to be an inherited, possibly autoimmune disorder that causes the . It has been estimated that the prevalence rate of multiple sclerosis in Europe is 83 out of 100,000. Moreover, it is more common among women than men. In addition to this, two million people in Europe are affected by RA, which is one of the most common forms of autoimmune diseases, affecting 21 million people worldwide. However, the societal burden of autoimmune diseases is difficult to estimate as most of these diseases are debilitating de·bil·i·tat·ing adj. Causing a loss of strength or energy. Debilitating Weakening, or reducing the strength of. Mentioned in: Stress Reduction , while some are less serious. "The growing patient population and the need for better treatment options are the major driving forces in the autoimmune diseases therapeutics market in Europe," notes the analyst of this research service. "The increased uptake of biologics by physicians is also likely to have a significant impact on the sales of autoimmune disease therapeutics." In addition, aggressive educational campaigns undertaken by pharmaceutical companies to promote new biologics are igniting interest among physicians and are expected to contribute to an increase in market revenues. Awareness Programmes Crucial for Market Growth Currently, the huge gap that exists between early diagnosis and the initiation of therapy is a critical factor restraining RESTRAINING. Narrowing down, making less extensive; as, a restraining statute, by which the common law is narrowed down or made less extensive in its operation. market growth. "The complex nature of autoimmune diseases hinders the development of drugs that can cure these diseases," explains the analyst. "This scenario is worsened by low awareness of autoimmune diseases among patients, as well as physicians." Thus, immense scope exists for improvement in translating the current knowledge of the autoimmune diseases to produce efficient therapeutics that can address the symptoms, as well as cure the disease." Accordingly, researchers are striving to develop better therapeutics to reduce the burden of autoimmune diseases. Meanwhile, various continuous medical education programmes will need to be conducted to inform the community about the implications of autoimmune diseases. These initiatives will promote the treatment of those affected with rheumatoid arthritis or multiple sclerosis and some form of drug for such autoimmune diseases can be administered to them. Content Outline: -1. Executive Summary -2. Research Methodology -3. Market Overview -4. Industry Challenges -5. Market Engineering Research for Multiple Sclerosis Market -6. Market Engineering Research for Rheumatoid Arthritis Market -7. Strategic Recommendations -8. Database of Key Industry Participants -9. Appendix For more information visit http://www.researchandmarkets.com/reports/c49960 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion